{
  "first_published_at": "2012-11-22", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON207191", 
  "title": "Human papillomavirus vaccine Cervarix: safety review shows balance of risks and benefits remains clearly positive", 
  "tags": "{\"parsed_therapeutic\": [\"immunology-vaccination\", \"cancer\"], \"Audience:\": [\"Primary care\"], \"Therapeutic area:\": [\"Immunology and vaccination\", \"Cancer\"]}", 
  "_document_number": 90, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/change_icon.png", 
  "therapeutic_area": [
    "immunology-vaccination", 
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Human papillomavirus vaccine Cervarix: safety review shows balance of risks and benefits remains clearly positive</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: November 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>A safety review conducted at the end of its routine use during the ongoing human papillomavirus immunisation programme has found that no new risks have been identified for Cervarix, and that the balance of its risks and benefits remains clearly positive. Cervarix was replaced in the programme by the HPV vaccine Gardasil&#9660; from September 2012.<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--Since September 2008 the human papillomavirus (HPV) vaccine Cervarix has been used extensively in the UK routine HPV immunisation programme to prevent cervical cancer. We have previously reported on the safety of the vaccine following the <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087699\" target=\"_blank\">first </a>and <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON096806\" target=\"_blank\">second</a> &#160;year of use.<br />\n<br />\nWhile its safety evaluation has been continuous, we conducted a further <a target=\"_blank\" href=\"/home/groups/pl-p/documents/websiteresources/con213228.pdf\">safety review of the totality of the UK experience with Cervarix up to the end of July 2012</a>. No new safety concerns were identified and the number and nature of adverse reaction (ADR) reports received was as expected after administration of at least 6 million doses of the vaccine in the UK.<br />\n<br />\nBefore Cervarix was first used the MHRA anticipated that a range of medical conditions naturally prevalent in the adolescent female population would occur in temporal association with vaccination and might be reported as suspect side effects. Statistical methods were therefore put in place to rapidly assess whether such reports were consistent with chance, or whether they could be new side effects of the vaccine.<br />\n<br />\nOne such condition was chronic fatigue syndrome (CFS) &#8211; the level of reporting for which was found to be well within the expected background incidence rate. An ecological study and a self-controlled case series study using the <a href=\"http://www.cprd.com/intro.asp\" target=\"_blank\">Clinical Practice Research Datalink </a>(CPRD) also did not find an increased risk of fatigue syndromes with Cervarix.<br />\n<br />\nOverall, the safety experience with Cervarix up to the end of July 2012 supports the previous conclusion that the balance of benefits and risks of Cervarix remains clearly positive.<br />\n<br />\nFrom September this year,<a href=\"http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_131607 \" target=\"_blank\"> the HPV vaccine Gardasil&#9660; replaced Cervarix in the national immunisation programme</a>. &#160;Gardasil&#9660; has been used extensively in other countries such as the United States. As with all vaccines and medicines we will closely monitor its safety during routine use in the UK.<br />\n<br />\n<br />\n<strong>Further information:</strong><br />\n<br />\n<a target=\"_blank\" href=\"/home/groups/pl-p/documents/websiteresources/con213228.pdf\">2012 Public Assessment Report on Cervarix: update on UK safety experience at end of 4 years use in HPV routine immunisation programme</a><br />\n<br />\n<a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-G-L/HumanpapillomavirusHPVvaccine/index.htm\">MHRA webpage on Cervarix safety information</a><br />\n<br />\n<a href=\"http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_133345\" target=\"_blank\">Factsheet and Q&#38;A document from DH</a><br />\n<br />\nBNF section 14.4: <a href=\"http://www.medicinescomplete.com/mc/bnf/current/PHP8317-human-papilloma-virus-vaccines.htm\" target=\"_blank\">Human papillomavirus vaccines</a><br />\n<br />\n<em>Article citation: Drug Safety Update November 2012, vol 6, issue 4: H2</em>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\tSince September 2008 the human papillomavirus (HPV) vaccine Cervarix has been used extensively in the UK routine HPV immunisation programme to prevent cervical cancer. We have previously reported on the safety of the vaccine following the <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087699\" target=\"_blank\">first</a>and <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON096806\" target=\"_blank\">second</a> &#160;year of use.<br>\n<br>\nWhile its safety evaluation has been continuous, we conducted a further <a target=\"_blank\" href=\"http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con213228.pdf\">safety review of the totality of the UK experience with Cervarix up to the end of July 2012</a>. No new safety concerns were identified and the number and nature of adverse reaction (ADR) reports received was as expected after administration of at least 6 million doses of the vaccine in the UK.<br>\n<br>\nBefore Cervarix was first used the MHRA anticipated that a range of medical conditions naturally prevalent in the adolescent female population would occur in temporal association with vaccination and might be reported as suspect side effects. Statistical methods were therefore put in place to rapidly assess whether such reports were consistent with chance, or whether they could be new side effects of the vaccine.<br>\n<br>\nOne such condition was chronic fatigue syndrome (CFS) &#8211; the level of reporting for which was found to be well within the expected background incidence rate. An ecological study and a self-controlled case series study using the <a href=\"http://www.cprd.com/intro.asp\" target=\"_blank\">Clinical Practice Research Datalink</a>(CPRD) also did not find an increased risk of fatigue syndromes with Cervarix.<br>\n<br>\nOverall, the safety experience with Cervarix up to the end of July 2012 supports the previous conclusion that the balance of benefits and risks of Cervarix remains clearly positive.<br>\n<br>\nFrom September this year,<a href=\"http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_131607\" target=\"_blank\">the HPV vaccine Gardasil&#9660; replaced Cervarix in the national immunisation programme</a>. &#160;Gardasil&#9660; has been used extensively in other countries such as the United States. As with all vaccines and medicines we will closely monitor its safety during routine use in the UK.<br>\n<br>\n<br>\n<strong>Further information:</strong><br>\n<br>\n<a target=\"_blank\" href=\"http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con213228.pdf\">2012 Public Assessment Report on Cervarix: update on UK safety experience at end of 4 years use in HPV routine immunisation programme</a><br>\n<br>\n<a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-G-L/HumanpapillomavirusHPVvaccine/index.htm\">MHRA webpage on Cervarix safety information</a><br>\n<br>\n<a href=\"http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_133345\" target=\"_blank\">Factsheet and Q&amp;A document from DH</a><br>\n<br>\nBNF section 14.4: <a href=\"http://www.medicinescomplete.com/mc/bnf/current/PHP8317-human-papilloma-virus-vaccines.htm\" target=\"_blank\">Human papillomavirus vaccines</a><br>\n<br>\n<em>Article citation: Drug Safety Update November 2012, vol 6, issue 4: H2</em>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-11-01", 
  "date_last_modified": "2013-02-06", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "safety review of the totality of the UK experience with Cervarix up to the end of July 2012", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con213228.pdf", 
      "filename": "downloads/abf3c10b926688ec5c4b6cc41c660974a05b9b35/con213228.pdf", 
      "original_filename": "con213228.pdf"
    }, 
    {
      "content_type": "application/pdf", 
      "title": "2012 Public Assessment Report on Cervarix: update on UK safety experience at end of 4 years use in HPV routine immunisation programme", 
      "assetid": 1, 
      "original_url": "http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con213228.pdf", 
      "filename": "downloads/abf3c10b926688ec5c4b6cc41c660974a05b9b35/con213228.pdf", 
      "original_filename": "con213228.pdf"
    }
  ], 
  "_item_id": 90, 
  "summary": "A safety review conducted at the end of its routine use during the ongoing human papillomavirus immunisation programme has found that no new risks have been identified for Cervarix, and that the balance of its risks and benefits remains clearly positive. Cervarix was replaced in the programme by the HPV vaccine Gardasil▼ from September 2012.", 
  "body": "Article date: November 2012 Since September 2008 the human papillomavirus (HPV) vaccine Cervarix has been used extensively in the UK routine HPV immunisation programme to prevent cervical cancer. We have previously reported on the safety of the vaccine following the [first](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087699)and [second](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON096806)  year of use.  \n  \nWhile its safety evaluation has been continuous, we conducted a further [ASSET_TAG](#ASSET0). No new safety concerns were identified and the number and nature of adverse reaction (ADR) reports received was as expected after administration of at least 6 million doses of the vaccine in the UK.  \n  \nBefore Cervarix was first used the MHRA anticipated that a range of medical conditions naturally prevalent in the adolescent female population would occur in temporal association with vaccination and might be reported as suspect side effects. Statistical methods were therefore put in place to rapidly assess whether such reports were consistent with chance, or whether they could be new side effects of the vaccine.  \n  \nOne such condition was chronic fatigue syndrome (CFS) – the level of reporting for which was found to be well within the expected background incidence rate. An ecological study and a self-controlled case series study using the [Clinical Practice Research Datalink](http://www.cprd.com/intro.asp)(CPRD) also did not find an increased risk of fatigue syndromes with Cervarix.  \n  \nOverall, the safety experience with Cervarix up to the end of July 2012 supports the previous conclusion that the balance of benefits and risks of Cervarix remains clearly positive.  \n  \nFrom September this year,[the HPV vaccine Gardasil▼ replaced Cervarix in the national immunisation programme](http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_131607).  Gardasil▼ has been used extensively in other countries such as the United States. As with all vaccines and medicines we will closely monitor its safety during routine use in the UK.  \n  \n  \nFurther information:  \n  \n[ASSET_TAG](#ASSET1)  \n  \n[MHRA webpage on Cervarix safety information](http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-G-L/HumanpapillomavirusHPVvaccine/index.htm)  \n  \n[Factsheet and Q&A document from DH](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_133345)  \n  \nBNF section 14.4: [Human papillomavirus vaccines](http://www.medicinescomplete.com/mc/bnf/current/PHP8317-human-papilloma-virus-vaccines.htm)  \n  \nArticle citation: Drug Safety Update November 2012, vol 6, issue 4: H2\n"
}